Shares of Moderna jumped 4.91% to $143.76 at 14:54 EST on Thursday, after three sequential sessions in a row of losses. The Nasdaq Stock Market is rising 0.68% to $12,744.50, after three sequential sessions in a row of gains. This seems, so far, a somewhat positive trend trading session today.

Moderna’s last close was $137.03, 24.17% below its 52-week high of $178.50.

News about Moderna today

FDA panel expected to back Moderna Covid-19 vaccine. According to today’s article on The Wall Street Journal, "A federal vaccine-advisory committee is likely to recommend that the Food and Drug Administration grant an emergency-use authorization for the new Covid-19 vaccine from Moderna Inc. when the panel meets Thursday, its chairman said."

Global market outlook for the coronavirus vaccine market to 2027, featuring Moderna inc, geovax, inovio pharmaceuticals and more. According to today’s article on Business Insider, "Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.", "Key Topics Covered:1 Executive Summary 2 Preface3 Market Trend Analysis4 Porters Five Force Analysis5 Global Coronavirus Vaccine Market, By Infection Type6 Global Coronavirus Vaccine Market, By Vaccine Type7 Global Coronavirus Vaccine Market, By Product Type8 Global Coronavirus Vaccine Market, By Route of Administration9 Global Coronavirus Vaccine Market, By Patient Type10 Global Coronavirus Vaccine Market, By End User11 Global Coronavirus Vaccine Market, By Geography12 Key Developments13 Company Profiling13.1 Inovio Pharmaceuticals, Inc. 13.2 Moderna, Inc. 13.3 Protein Potential, LLC 13.4 Novavax, Inc. 13.5 Synairgen PLC 13.6 AlphaVax, Inc. 13.7 NanoViricides, Inc. 13.8 Zydus Cadila 13.9 Bravovax 13.10 GeoVax 13.11 Altimmune 13.12 Janssen Pharmaceutical Companies 13.13 CanSino Biologics 13.14 Vaxart 13.15 Vaxil Bio Ltd For more information about this report visit https://www.researchandmarkets.com/r/5b6t0s"

Moderna’s Sales

Moderna’s sales growth is 1665.3% for the present quarter and 15587.1% for the next. The company’s growth estimates for the current quarter is a negative 29.7% and positive 685.7% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $143.76 at 14:54 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s value is way higher than its 50-day moving average of $110.24 and way higher than its 200-day moving average of $79.01.

Previous days news about Moderna

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to The Wall Street Journal on Tue Dec 15, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to Bloomberg Quint on Tue Dec 15, "The shot must be kept extremely cold and requires special freezers to transport, while Moderna’s can be kept in more traditional cold storage.", "The FDA got a much deeper look at Moderna’s clinical-trial data than the numbers previously released to the public by the company. "

Moderna vaccine found safe, effective before key FDA review. According to Bloomberg Quint on Tue Dec 15, "Moderna’s vaccine will be distributed to sites around the country where health-care workers and residents of long-term care facilities, such as nursing homes, are expected to get the earliest doses.", "Moderna Inc.’s vaccine is safe and effective for preventing Covid-19 in people ages 18 and older, U.S. regulators said, clearing the way for a second shot to quickly gain emergency authorization and add to the country’s sprawling immunization effort."

Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to MarketWatch on Tue Dec 15, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company’s COVID-19 vaccine candidate is “highly effective” at preventing infections with the coronavirus. "

Canada to receive early access to Moderna Covid-19 vaccine. According to Business Insider on Tue Dec 15, "Today, the Honourable Anita Anand, Minister of Public Services and Procurement, announced that following successful negotiations and contingent on Health Canada authorization of the vaccine, Canada will be able to access 168,000 doses of the Moderna COVID-19 vaccine in December 2020.", "These are part of the guaranteed 40 million doses, and up to a total of 56 million doses, that Canada has secured through its existing agreement with Moderna. "

Moderna to offer covid shots to volunteers who got placebo. According to Bloomberg Quint on Tue Dec 15, "Moderna Inc. is preparing to offer its Covid-19 shot to trial participants who received a placebo in the final-stage study once the vaccine is authorized for emergency use in the U.S.", "Ray Jordan, a Moderna spokesman, confirmed the letter was being prepared."

Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Moderna (MRNA) – Moderna was downgraded to "hold" from "buy" at Jefferies, which cited the significant runup in the drugmaker’s stock as well as high expectations surrounding its Covid-19 vaccine. "

Moderna party ending, analysts caution before shot approval. According to Bloomberg Quint on Wed Dec 16, "Moderna’s shot will face a Food and Drug Administration panel on Thursday, and soon after the vaccine is likely to get regulatory clearance.", "Moderna now has nine buys, seven holds and two sell ratings, according to data compiled by Bloomberg."

LEAVE A REPLY

Please enter your comment!
Please enter your name here